近日,据央视报道,接受我国首款也是目前唯一获批的干细胞药品艾米迈托赛注射液治疗的首位患者已顺利出院。记者获悉,自艾米迈托赛注射液首方在北京开出以来,在阿里健康的推动下,艾米迈托赛注射液的药品服务已实现全国范围的广泛覆盖。当前,广东等20多个省份的患者,可通过平台进行预约。艾米迈托赛注射液由国内企业铂生生物研发,适应症为14岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病(aGVHD)。今年6...
Source Link近日,据央视报道,接受我国首款也是目前唯一获批的干细胞药品艾米迈托赛注射液治疗的首位患者已顺利出院。记者获悉,自艾米迈托赛注射液首方在北京开出以来,在阿里健康的推动下,艾米迈托赛注射液的药品服务已实现全国范围的广泛覆盖。当前,广东等20多个省份的患者,可通过平台进行预约。艾米迈托赛注射液由国内企业铂生生物研发,适应症为14岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病(aGVHD)。今年6...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.